Endpoints | Non-Rapid CAV (n=84) | Rapid CAV (n=8) | P-Value |
---|---|---|---|
Subsequent 1-Year Actual Survival | 94.9% | 75.0%* | 0.025 |
Subsequent 1-Year Actual Freedom from NF-MACE | 88.0% | 87.5% | 0.970 |
Subsequent 1-Year Actual Freedom from de novo DSA | 100.0% | 100.0% | 1.000 |
*p<0.05 compared Non-Rapid CAV.